Form 10-Q HEMISPHERX BIOPHARMA For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Hemispherx Biopharma (HEB) Reports Q1 Loss of $0.02/Share
May 13, 2015 9:24 AM EDTHemispherx Biopharma (NYSE: HEB) reported Q1 EPS of ($0.02), versus ($0.02) reported last year.
Cash, cash equivalents and marketable securities were approximately $17,005,000 at March 31, 2015 as compared to $16,108,000 as of December 31, 2014.
For earnings history and earnings-related data on Hemispherx Biopharma (HEB) click here.
... More